Treatment options for PNET liver metastases. a systematic review [PDF]
, 2018 Pancreatic neuroendocrine tumors (PNETs) are rare pancreatic neoplasms. About 40-80% of patients with PNET are metastatic at presentation, usually involving the liver (40-93%). Liver metastasis represents the most significant prognostic factor.
Aurello, Paolo +8 more
core +1 more source
Computational simulation of the predicted dosimetric impact of adjuvant yttrium-90 PET/CT-guided percutaneous ablation following radioembolization [PDF]
, 2016 Background: 90Y PET/CT post-radioembolization imaging has demonstrated that the distribution of 90Y in a tumor can be non-uniform. Using computational modeling, we predicted the dosimetric impact of post-treatment 90Y PET/CT-guided percutaneous ablation ...
Abigail Lin +5 more
core +2 more sources
Beyond Hepatocellular Carcinoma and Colorectal Metastasis: The Expanding Applications of Radioembolization [PDF]
, 2014 As a relatively safe outpatient procedure, radioembolization can potentially be used to treat any type of tumor within the liver, primary or metastatic.
Ganguli, Suvranu, Zurkiya, Omar
core +2 more sources
Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma Who have Previously Received Sorafenib [PDF]
, 2013 Purpose: Yttrium-90 radioembolization (RE) is a locoregional therapy option for hepatocellular carcinoma (HCC). Sorafenib is a multikinase inhibitor used in HCC that can potentially affect the efficacy of RE by altering tumor vascularity or suppressing ...
Bazylewicz, Michael +7 more
core +2 more sources
A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. [PDF]
, 2015 Hepatocellular carcinoma (HCC), the second leading cause of cancer deaths worldwide, is difficult to treat and highly lethal. Since HCC is predominantly diagnosed in patients with cirrhosis, treatment planning must consider both the severity of liver ...
Busuttil, Ronald W +2 more
core +2 more sources
Yttrium-90 radioembolization for the treatment of unresectable liver cancer: Results of a single center [PDF]
, 2014 Objective: To determine the effects of yttrium-90 (Y-90) resin microsphere radioembolization therapy on patients with unresectable liver cancer who do not benefit from chemotherapy.
Hakan Şat Bozcuk +4 more
core +1 more source
Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection [PDF]
, 2014 Introduction: For patients with resectable hepatocellular carcinoma (HCC), hepatectomy remains one of the best treatment options to provide long-term survival.
Chan, ACY +10 more
core +1 more source
Phantom validation of quantitative Y-90 PET/CT based dosimetry in liver radioembolisation [PDF]
, 2017 Background PET/CT has recently been shown to be a viable alternative to traditional post-infusion imaging methods providing good quality images of 90Y-laden microspheres after selective internal radiation therapy (SIRT).
Bagni, Oreste +17 more
core +3 more sources
Radiological Loco‐Regional Treatments for Cholangiocarcinoma: A Systematic Review of the Literature
Liver International, Volume 46, Issue 4, April 2026.ABSTRACT Cholangiocarcinoma (CCA) is the second most common primary liver cancer and is being diagnosed with increasing frequency worldwide. We performed a systematic review on radiofrequency (RFA), microwave (MWA), irreversible electroporation (IRE), trans‐arterial chemoembolization (TACE) and selective internal radiation therapy (SIRT) in CCA. Thirty‐
Dimitrios Pallas +6 more
wiley +1 more source
ChemBioChem, Volume 27, Issue 1, January 2026.Radiopharmaceuticals enable precise cancer diagnosis and targeted therapy by combining radioactive isotopes with carrier molecules. This review summarizes advances from 2014 to 2025, emphasizing probe design, click chemistry, novel targets, and nanodelivery systems.
Mohd Sayeed Shaikh +7 more
wiley +1 more source